Werewolf Therapeutics, Inc. (HOWL) earnings
HOWL earnings moved a median of -3.65% by the close. Quarterly and annual HOWL reports and results, each read against the price at its own news timestamp. Back to the HOWL overview →
21 measured HOWL earnings events.
Where these HOWL earnings landedvs 21 measured HOWL earnings reactions
| Middle 50% of HOWL earnings reactions | -5.70% to -0.45% |
|---|---|
| Median reaction (to close) | -3.65% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 HOWL earnings events with a measured close landed between -5.70% and -0.45%; 24% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Werewolf Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -6.06% | -29.38% | |
| Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates | Press release | -6.06% | -29.38% | |
| Form 10-Q Werewolf Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +9.85% | +9.98% | |
| Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates | Press release | +9.85% | +9.98% | |
| Form 10-K Werewolf Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -0.71% | -7.05% | |
| Form 10-Q Werewolf Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -3.57% | -3.97% | |
| Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | -3.57% | -3.97% | |
| Form 10-Q Werewolf Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -3.65% | |
| Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | +0.00% | -3.65% | |
| Form 10-Q Werewolf Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.26% | -5.70% | |
| Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | +0.26% | -5.70% | |
| Form 10-K Werewolf Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -1.63% | +2.44% | |
| Form 10-Q Werewolf Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -4.62% | -5.88% | |
| Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | Press release | -4.62% | -5.88% | |
| Form 10-Q Werewolf Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +1.68% | +3.35% | |
| Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update | Press release | +1.68% | +3.35% | |
| Form 10-Q Werewolf Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +1.39% | -0.98% | |
| Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update | Press release | +1.39% | -0.98% | |
| Form 10-K Werewolf Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -0.93% | -3.57% | |
| Form 10-Q Werewolf Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +4.95% | -0.45% | |
| Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update | Press release | +4.95% | -0.45% |
Keep exploring
More HOWL: analyst actions → · SEC filings → · HOWL overview →